Regulatory Delay Casts Shadow Over Life‑Saving Therapies for Indian Children with Spinal Muscular Atrophy

Spinal muscular atrophy, a genetically mediated neuromuscular disorder characterised by progressive loss of motor neurons, afflicts a modest but poignant segment of India's pediatric population, leaving affected children dependent upon mechanical ventilation and intensive caregiving.

The United Kingdom's National Institute for Health and Care Excellence, after protracted assessment of clinical trial data and cost‑effectiveness modelling, issued final draft guidance endorsing the use of two recently developed biologics, each capable of extending survival and, in select cases, improving motor function among infants diagnosed early.

In stark contrast, India’s Central Drugs Standard Control Organisation, while formally recognising the therapeutic promise of the same agents, has yet to conclude its pharmacovigilance review, a delay that perpetuates a de facto denial of access for families unable to procure the medicines through private importation channels.

Consequently, numerous households situated in rural districts, already burdened by limited public health infrastructure and intermittent electricity for ventilatory support, confront the untenable prospect of financing multimillion‑rupee treatment courses, thereby exacerbating entrenched socioeconomic disparities and jeopardising the educational attainment of siblings forced into caregiving roles.

The Ministry of Health and Family Welfare, invoking the National Health Protection Mission, has publicly pledged to accelerate the incorporation of life‑saving orphan drugs into state‑run programmes, yet concrete timelines remain conspicuously absent, prompting civil‑society observers to question the sincerity of proclamations against a backdrop of fiscal conservatism.

Non‑governmental organisations, ranging from paediatric neurologist‑led advocacy groups to charitable foundations specialising in rare disease funding, have mobilised petitions, legal notices, and media campaigns, thereby exposing the disconnect between statutory obligations and operational realities within India’s federated health architecture.

The protracted postponement of regulatory clearance for the SMA therapies, notwithstanding unequivocal efficacy data presented to international peers, underscores a systemic inertia that contravenes the constitutional guarantee of health as a fundamental right under Article 21 of the Constitution. Such administrative apathy invites judicial scrutiny, for the Supreme Court has previously mandated that the state must not arbitrarily withhold access to essential medicines where reasonable alternatives exist and public interest is demonstrably at stake. Should the Union Health Ministry, invoking its statutory duty under the Clinical Trials Registry‑India and the Drugs and Cosmetics Act, be compelled to disclose transparent criteria and timelines for the approval of orphan drugs that have secured licensure in peer jurisdictions? Might the Right to Information Act be employed by affected families to obtain substantive evidence that budgetary allocations earmarked for rare disease interventions are not being diverted, thereby ensuring fiscal accountability within the Ministry of Health's expenditure framework? Would a writ of mandamus, filed by a coalition of patient advocacy organisations, constitute an appropriate legal instrument to compel the regulatory authority to act within a reasonable period, thereby aligning administrative practice with the procedural fairness envisaged by Article 14's guarantee against arbitrary state action?

The disparity between the swift incorporation of these orphan drugs into the United Kingdom's publicly funded health system and the protracted deliberations within India's regulatory framework crystallises a broader inequity in global health governance, wherein resource‑rich nations reap the benefits of accelerated access while low‑and middle‑income populations remain marginalized. Does the principle of universal health coverage, enshrined in the Sustainable Development Goals and echoed in India's own National Health Policy, obligate the government to allocate sufficient financial resources for high‑cost orphan medicines, or does it permit selective prioritisation that effectively excludes rare disease patients from equitable care? Might the establishment of an independent, time‑bound review panel, comprising clinicians, pharmacoeconomists, and patient representatives, serve as a procedural safeguard against undue delay, thereby reconciling the competing demands of fiscal prudence and the moral imperative to preserve life? Will the forthcoming parliamentary oversight committee, tasked with evaluating the implementation of the National Health Protection Scheme, interrogate the adequacy of existing mechanisms for the procurement and distribution of ultra‑expensive therapies, or will it merely reaffirm existing policy rhetoric without effecting substantive reform?

Published: May 14, 2026

Published: May 14, 2026